Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Many pharmacologic/efficacy and safety-mechanism claims for Wegovy are consistent with the provided label excerpts (e.g., GLP-1 receptor agonist, approved indications, key warnings/adverse reactions). However, several claims are not supported by the provided labeling sections and there are notable gaps in label compliance coverage (e.g., dosing/administration, full contraindications context for pancreatitis history, and several non-label business/exclusivity statements).
Category Scores
Accurate Statements
Wegovy is a GLP-1 receptor agonist.
Supported by provided label excerpts: 12.1 Mechanism of Action; 11 Description.
Clinical trials have shown Wegovy to be effective in significant weight loss.
Supported by provided label excerpts: 1 Indications and Usage and 14.2 Results for weight reduction.
Wegovy is effective in significant weight loss often in conjunction with diet and exercise.
Supported by provided label excerpts: 1 Indications and Usage (combination with reduced calorie diet and increased physical activity) and 14.2.
Wegovy is approved for chronic weight management in adults with obesity or who are overweight and have at least one weight-related condition (including high blood pressure, type 2 diabetes, or high cholesterol).
Supported by provided label excerpts: 1 Indications and Usage.
Wegovy is indicated for weight management in adolescents aged 12 and older with obesity.
Supported by provided label excerpts: 1 Indications and Usage.
Common side effects of Wegovy include nausea, vomiting, diarrhea, constipation, and abdominal pain.
Supported by provided label excerpts: 6.1 Clinical Trials Experience (GI reactions described; Table 3 includes these).
More serious side effects of Wegovy can include pancreatitis.
Supported by provided label excerpts: 5.2 Acute Pancreatitis.
More serious side effects of Wegovy can include gallbladder problems.
Supported by provided label excerpts: 5.3 Acute Gallbladder Disease.
More serious side effects of Wegovy can include kidney disease.
Supported by provided label excerpts: 5.5 Acute Kidney Injury Due to Volume Depletion.
More serious side effects of Wegovy can include thyroid tumors.
Supported by provided label excerpts: boxed warning / 5.1 Risk of Thyroid C-cell Tumors.
Patients with a personal or family history of medullary thyroid carcinoma or MEN 2 should not use Wegovy.
Supported by provided label excerpts: Contraindications and boxed warning.
Semaglutide (Wegovy's active ingredient) is a GLP-1 receptor agonist.
Supported by provided label excerpts: 11 Description; 12.1 Mechanism of Action.
Semaglutide mimics the action of the natural GLP-1 hormone.
Supported by provided label excerpts: 12.1 Mechanism of Action (GLP-1 analogue and GLP-1 receptor targeting).
The natural GLP-1 hormone helps regulate appetite and food intake by acting on the brain.
Supported by provided label excerpts: 12.1 Mechanism of Action (GLP-1 regulator of appetite and caloric intake; brain regions).
Clinical trials investigate semaglutide's potential cardiovascular benefits.
Supported by provided label excerpts: 14.1 Cardiovascular Outcomes Trial (MACE/CV outcomes).
Unsupported Statements
The primary patent for Wegovy's active ingredient (semaglutide) is set to expire in December 2031.
Absent from the provided FDA-approved prescribing information excerpts.
Other patents related to Wegovy's formulation and methods of use may extend market exclusivity beyond December 2031.
Absent from the provided FDA-approved prescribing information excerpts.
Patent expiry typically allows other companies to develop and market generic versions of a drug.
Absent from the provided FDA-approved prescribing information excerpts.
Patent expiry could lead to lower prices and increased accessibility for patients.
Absent from the provided FDA-approved prescribing information excerpts.
Numerous other patents protect aspects of semaglutide, including its manufacturing process, specific formulations (such as the subcutaneous injection pen), and therapeutic uses.
Absent from the provided FDA-approved prescribing information excerpts.
Patent protection mechanisms and potential legal challenges could influence the actual market entry date for generics.
Absent from the provided FDA-approved prescribing information excerpts.
Regulatory exclusivities granted by agencies like the FDA can provide periods of market protection separate from patent terms.
Absent from the provided FDA-approved prescribing information excerpts.
Ozempic is a drug that includes semaglutide and is used for diabetes.
Not supported by the provided Wegovy prescribing information excerpts; other product details are not in the provided label.
Tirzepatide is found in Mounjaro and Zepbound.
Not supported by the provided Wegovy prescribing information excerpts; other product details are not in the provided label.
Semaglutide slows down gastric emptying, contributing to a feeling of fullness.
Not supported by the provided label excerpts shown (mechanism section text provided does not include gastric emptying/fullness).
Wegovy is a high-cost medication.
Absent from the provided FDA-approved prescribing information excerpts.
Wegovy patient access depends on insurance coverage and pharmacy benefit plans.
Absent from the provided FDA-approved prescribing information excerpts.
Wegovy prices can vary significantly based on dosage and insurance plans.
Absent from the provided FDA-approved prescribing information excerpts.
Wegovy is manufactured by Novo Nordisk.
Not supported by the provided label excerpts; company/manufacturing details are not included in the sections provided.
Wegovy is not recommended for patients with a history of pancreatitis.
The provided excerpts include pancreatitis as an observed adverse reaction and management (monitor/discontinue if suspected pancreatitis) but do not show any explicit 'not recommended' statement regarding prior pancreatitis.
GLP-1 receptor agonists work by mimicking hormones that regulate appetite and blood sugar.
Partially supported at most: 12.1 supports appetite/food intake regulation and GLP-1 receptor activity, but the provided label text does not explicitly support the 'blood sugar' phrasing as stated.
Novo Nordisk continues to conduct clinical trials to explore new uses and refine existing ones for semaglutide.
Absent from the provided FDA-approved prescribing information excerpts.
Contradictions
Important Omissions
Dosing and administration details for WEGOVY (e.g., titration, dosing schedule, injection vs tablet instructions) were not evaluated and none of the extracted claims provide dosing-accurate label content.
Importance:
High
Contraindications context beyond thyroid C-cell tumor/MTC and hypersensitivity (e.g., any other contraindications present in the full label text) was not comprehensively evaluated; the pancreatitis-history 'not recommended' statement may indicate missing label nuance.
Importance:
Moderate
Monitoring recommendations were not covered (e.g., renal function monitoring language exists in provided excerpts but was not addressed by extracted claims).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Label-aligned safety statements were captured for major boxed warning (thyroid C-cell tumors) and several serious adverse events (pancreatitis, gallbladder disease, acute kidney injury). However, an 'avoid if prior pancreatitis' claim was treated as unsupported by provided excerpts, and multiple non-label claims were included (e.g., pricing/access/exclusivity), which could dilute label-accurate risk communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Substantial portion of extracted claims are absent from the provided prescribing information excerpts, and one mechanism statement is only partially supported by the provided label language. Dosing/administration and monitoring sections were not adequately assessed.
Suggested Improvement
Restrict labeling-adherence evaluation to claims that are explicitly present in the provided label sections, verify exact wording for mechanism and pancreatitis-related 'not recommended' language in the full contraindications/warnings text, and add targeted checks for dosing/administration and monitoring language.